



Medical Care Subcommittee
Friday, February 6, 2026
9:30 a.m. – 11:30 a.m.
Behavioral Science Research
2121 Ponce de Leon Blvd., Ste. 240
Miami, FL 33134

AGENDA

I.	Call to Order	James Dougherty
II.	Introductions	All
III.	Meeting Housekeeping	James Dougherty
IV.	Floor Open to the Public	Cristhian Ysea
V.	Review/Approve Agenda	All
VI.	Review/Approve Minutes of January 23, 2026	All
VII.	Standing Business	
	• Response to the 2026 ADAP Program Changes- Updates	All
	• Formulary Reviews and Prioritization	All
	○ Oral Health Formulary	
	○ Prescription Drugs Formulary	
	○ Allowable Conditions	
VIII.	Announcements	All
IX.	Next Meeting: February 27, 2026 at BSR	Cristhian Ysea
X.	Adjournment	James Dougherty

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



Medical Care Subcommittee
Friday, February 6, 2026
9:30 a.m. – 11:30 a.m.
Behavioral Science Research
2121 Ponce de Leon Blvd., Ste. 240
Miami, FL 33134

AGENDA

- | | | |
|-------|--|-----------------|
| I. | Call to Order | James Dougherty |
| II. | Introductions | All |
| III. | Meeting Housekeeping | James Dougherty |
| IV. | Floor Open to the Public | Cristhian Ysea |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 23, 2026 | All |
| VII. | Standing Business | |
| | • Response to the 2026 ADAP Program Changes- Updates | All |
| | • Formulary Reviews and Prioritization | All |
| | ○ Oral Health Formulary | |
| | ○ Prescription Drugs Formulary | |
| | ○ Allowable Conditions | |
| VIII. | Announcements | All |
| IX. | Next Meeting: February 27, 2026 at BSR | Cristhian Ysea |
| X. | Adjournment | James Dougherty |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



Medical Care Subcommittee

Friday, February 6, 2026

9:30 a.m. – 11:30 a.m.

Behavioral Science Research

2121 Ponce de Leon Blvd., Ste. 240

Miami, FL 33134

AGENDA

- | | | |
|-------|--|-----------------|
| I. | Call to Order | James Dougherty |
| II. | Introductions | All |
| III. | Meeting Housekeeping | James Dougherty |
| IV. | Floor Open to the Public | Cristhian Ysea |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 23, 2026 | All |
| VII. | Standing Business | |
| | • Response to the 2026 ADAP Program Changes- Updates | All |
| | • Formulary Reviews and Prioritization | All |
| | ○ Oral Health Formulary | |
| | ○ Prescription Drugs Formulary | |
| | ○ Allowable Conditions | |
| VIII. | Announcements | All |
| IX. | Next Meeting: February 27, 2026 at BSR | Cristhian Ysea |
| X. | Adjournment | James Dougherty |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

Meeting Housekeeping Medical Care Subcommittee

Created by Behavioral Science Research

Disclaimer and Code of Conduct

- ❑ Audio of this meeting is being recorded and will become part of the public record.
- ❑ Members serve the interest of the Miami-Dade HIV/AIDS community as a whole.
- ❑ Members do not serve private or personal interests, and shall endeavor to treat all persons, issues and business in a fair and equitable manner.
- ❑ Members shall refrain from side-bar conversations in accordance with Florida Government in the Sunshine laws.

General Housekeeping

- ❑ You must sign in to be counted as present.
- ❑ Place cell phones on mute or vibrate - *If you must take a call, please excuse yourself from the meeting.*
- ❑ See staff after the meeting if you are interested in membership or if you have a question that wasn't covered during the meeting.

About the Partnership

- ❑ The Miami-Dade HIV/AIDS Partnership is the official Ryan White Program Planning Council for Miami-Dade County.
- ❑ Partnership Members are appointed by the Mayor of Miami-Dade County based on recommendations by the Community Coalition.
- ❑ The Medical Care Subcommittee reports to the Care and Treatment Committee. The Care and Treatment Committee is one of six Standing Committees of the Partnership.
- ❑ All Partnership and Standing Committee members are volunteers and commit to abiding by the Partnership's Bylaws, including regular meeting attendance and completion of required training and paperwork.
- ❑ See staff after the meeting for additional details.



Meeting Participation

Everyone has a role to play!

- ❑ All attendees may address the board as time allows and at the discretion of the Chair.
- ❑ Please *share your expertise* on the current Agenda topics and motions. Remember to . . .
 - Raise your hand to be recognized by the Chair or added to the queue during discussions.
 - Avoid repeating points previously addressed.
- ❑ Only Medical Care Subcommittee members vote at today's meeting.
- ❑ Announcements can be made at the end of the meeting as time allows. Announcements should inform or educate the community and must not be used to advance personal interests or any form of financial gain.

Language Matters!

In today's world, there are many words that can be stigmatizing. Here are a few suggestions for better communication.



Remember **People First** Language . . .

People with HIV, **People** with substance use disorders,
People who are unhoused, etc.

Please don't say **RISKS** . . . Instead, say **REASONS**.
Please don't say, **INFECTED with HIV** . . . Instead, say
ACQUIRED HIV, DIAGNOSED with HIV, or
CONTRACTED HIV.

Please **do not** use these terms . . .

Dirty . . . Clean . . . Full-blown AIDS . . . Victim . . . 6

Meeting Terminology

Meetings can be fast-paced and confusing!

- ❑ Terms and acronyms you might hear at today's meeting are on the back of your Agenda.
- ❑ Please raise your hand at any time if you need more information!

	
Meeting Guide	
Meetings can be fast-paced and confusing! These terms and acronyms can help you follow along. Please raise your hand at any time if you need more information!	
Partnership, PC, or Planning Council	The Miami-Dade HIV/AIDS Partnership - Official Ryan White Program Planning Council in Miami-Dade County
RWP or RWHAP	The Ryan White Program or The Ryan White HIV/AIDS Program (Usually referring to Part A/MAI).
ADAP	AIDS Drug Assistance Program. Provides FDA-approved medications for low-income individuals with HIV who have limited or no coverage from private insurance or Medicaid. Provides insurance coverage for uninsured RWP clients.
BSR	Behavioral Science Research Corp. (aka, Staff).
EHE	Ending the HIV Epidemic: A Plan for America. Four Pillars: 1. Diagnose, 2. Treat, 3. Prevent, 4. Respond.
EMA	Eligible Metropolitan Area (locally, Miami-Dade County).
FDOH or FDOH-MDC	Florida Department of Health in Miami-Dade County.
FPL	Federal Poverty Level. Used to determine RWP eligibility and benefits.
HOPWA	Housing Opportunities for People with AIDS Program. Federal program that provides funding to support housing and housing-related services for people with AIDS and their families. Related terms: STRMU: Short-Term Rental, Mortgage and Utilities Assistance; Project-based: Funds designated units in a building; LTRA: Long-Term Rental Assistance (voucher program); and FMR: Fair Market Rents.
HRSA	The Health Resources and Services Administration. The source of federal RWP grant funds.
Integrated Plan or IP	The Miami-Dade County Integrated HIV Prevention and Care Plan.
JIPRT	The Joint Integrated Plan Review Team (Prevention Committee & Strategic Planning Committee).
MAI	Minority AIDS Initiative. Additional RWP funding to improve access to HIV care and health outcomes for disproportionately affected racial and ethnic minority populations.
NHAS	National HIV/AIDS Strategy. Four Goals: 1. Prevent new HIV infections; 2. Improve HIV-related health outcomes of people with HIV; 3. Reduce HIV-related disparities and health inequities; 4. Achieve integrated, coordinated efforts that address the HIV epidemic among all partners.
PE-Miami or Provide Enterprise	Provide Enterprise® by Groupware Technologies (RWP client database system).
The Recipient, The County, or OMB	The Miami-Dade County Office of Management and Budget. The Recipient of RWP Part A/MAI funds from HRSA.
TTRA	Test and Treat/Rapid Access. Protocol designed to ensure newly diagnosed people or those returning to care will obtain immediate linkage to medical care and treatment.
More terminology at www.aidsnet.org/the-partnership/#getonboard1 .	

Resources

- ❑ Behavioral Science Research Corp. (BSR) staff are the Resource Persons for this meeting.
- ❑ See staff after the meeting if you are interested in membership or if you have a question that wasn't covered during the meeting.
- ❑ Today's presentation and supporting documents are online at <https://partnershipmiami.org/the-partnership-2/#mcsc1> or by scanning the QR code on your agenda.

Medical Care Subcommittee (MCSC)

Next Meeting: November 21, 2025, at 9:30 a.m.

Behavioral Science Research Corporation, 2121 Ponce de Leon Boulevard, Suite 240, Coral Gables, FL 33134

AGENDA November 21, 2025

MINUTES October 24, 2025

PARTNERSHIP REPORT Partnership Report of Approved Motions, December 8, 2025

BYLAWS Click here.


RETURN TO MENU

Meeting Documents

- 2026 Officer Elections Memo
- Miami-Dade County RWP Oral Health Care Standards
- Oral Health Care Service Description – Draft
- OpenEvidence Review of Ryan White Allowable Conditions List for the Medical Care Subcommittee-November 2025
- Mental Health Services Service Description – Draft
- Substance Abuse Outpatient Care and Substance Abuse Services (Residential) Service Description – Draft
- RWP Letter of Medical Necessity for Dental Implants
- RWP Letter of Medical Necessity for Continuous Glucose Monitoring (CGM) Devices
- RWP Nutritional Assessment Letter for Extension of Occurrences of Food Bank Services
- Allowable Medical Conditions List
- Allowable Conditions Evaluation 2025
- Dear Colleague Letter from HRSA Administrator Thomas J. Engels
- RWP MDC Minimum Primary Medical Care Standards
- Request for Opinion on Client with Lipodystrophy
- 2026 MCSC Calendar of Activities

Next MCSC Meeting Coming Up In...

010: 22 : 24 : 24
Day Hrs Min Sec





Medical Care Subcommittee
Friday, February 6, 2026
9:30 a.m. – 11:30 a.m.
Behavioral Science Research
2121 Ponce de Leon Blvd., Ste. 240
Miami, FL 33134

AGENDA

- | | | |
|-------|--|-----------------|
| I. | Call to Order | James Dougherty |
| II. | Introductions | All |
| III. | Meeting Housekeeping | James Dougherty |
| IV. | Floor Open to the Public | Cristhian Ysea |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 23, 2026 | All |
| VII. | Standing Business | |
| | • Response to the 2026 ADAP Program Changes- Updates | All |
| | • Formulary Reviews and Prioritization | All |
| | ○ Oral Health Formulary | |
| | ○ Prescription Drugs Formulary | |
| | ○ Allowable Conditions | |
| VIII. | Announcements | All |
| IX. | Next Meeting: February 27, 2026 at BSR | Cristhian Ysea |
| X. | Adjournment | James Dougherty |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

Floor Open to the Public

“Pursuant to Florida Sunshine Law, I want to provide the public with a reasonable opportunity to be heard on any item on our agenda today. If there is anyone who wishes to be heard, I invite you to speak now. Each person will be given three minutes to speak. Please begin by stating your name and address for the record before you talk about your concerns.

“BSR has a dedicated line for statements to be read into the record. No statements were received.”



Medical Care Subcommittee
Friday, February 6, 2026
9:30 a.m. – 11:30 a.m.
Behavioral Science Research
2121 Ponce de Leon Blvd., Ste. 240
Miami, FL 33134

AGENDA

- | | | |
|-------|--|-----------------|
| I. | Call to Order | James Dougherty |
| II. | Introductions | All |
| III. | Meeting Housekeeping | James Dougherty |
| IV. | Floor Open to the Public | Cristhian Ysea |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 23, 2026 | All |
| VII. | Standing Business | |
| | • Response to the 2026 ADAP Program Changes- Updates | All |
| | • Formulary Reviews and Prioritization | All |
| | ○ Oral Health Formulary | |
| | ○ Prescription Drugs Formulary | |
| | ○ Allowable Conditions | |
| VIII. | Announcements | All |
| IX. | Next Meeting: February 27, 2026 at BSR | Cristhian Ysea |
| X. | Adjournment | James Dougherty |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



Medical Care Subcommittee
Friday, February 6, 2026
9:30 a.m. – 11:30 a.m.
Behavioral Science Research
2121 Ponce de Leon Blvd., Ste. 240
Miami, FL 33134

AGENDA

- | | | |
|-------|--|-----------------|
| I. | Call to Order | James Dougherty |
| II. | Introductions | All |
| III. | Meeting Housekeeping | James Dougherty |
| IV. | Floor Open to the Public | Cristhian Ysea |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 23, 2026 | All |
| VII. | Standing Business | |
| | • Response to the 2026 ADAP Program Changes- Updates | All |
| | • Formulary Reviews and Prioritization | All |
| | ○ Oral Health Formulary | |
| | ○ Prescription Drugs Formulary | |
| | ○ Allowable Conditions | |
| VIII. | Announcements | All |
| IX. | Next Meeting: February 27, 2026 at BSR | Cristhian Ysea |
| X. | Adjournment | James Dougherty |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



**Medical Care Subcommittee Meeting
Behavioral Science Research
2121 Ponce de Leon Boulevard, Suite 215
Coral Gables, FL 33134**

January 23, 2026 Minutes

#	Members	Present	Absent	Guests	
1	Baez, Ivet		X	Alcala, Carolina	Urbino, Karla
2	Dougherty, James	X		Cunningham, Trevor	Valle-Schwenk, Carla
3	Friedman, Lawrence	X		Gonzalez de Obando, Tivisay	Wall, Dan
4	Miller, Juliet	X		Hardeep Singh	Wilson, Max
5	Rojas, Vanessa	X		Mcpahell, Alester	
6	Romero, Javier	X		Nieto, Ana Maria	
7	Serrano-Irizarry, Yendi	X		Oquendo, Lirian	
8	Ysea, Cristhian A.	X		Ortiz, Angela	
Quorum: 4				Staff	
				Gattorno, Frank	Ladner, Robert
				Hilton, Karen	Meizoso, Marlen
				Lucas, Morela	

All documents referenced in these minutes were accessible to both members and the general public prior to and during the meeting, at <https://partnershipmiami.org/the-partnership-2/#mcsc1>.

I. Call to Order

James Dougherty

The Chair, James Dougherty, called the meeting to order at 9:44 a.m. He introduced himself, provided an overview of the work for the day's meeting, and welcomed everyone.

II. Introductions

All

Mr. Dougherty requested that members, guests, and staff introduce themselves.

III. Meeting Housekeeping

James Dougherty

Mr. Dougherty reviewed the meeting housekeeping presentation, including people first language, meeting protocols, location of Subcommittee meeting items online, and identification of resource persons.

IV. Floor Open to the Public

Cristhian Ysea

The Vice Chair, Cristhian Ysea, read the following:

“Pursuant to Florida Sunshine Law, I want to provide the public with a reasonable opportunity to be heard on any item on our agenda today. If there is anyone who wishes to be heard, I invite you to speak now. Each person will be given three minutes to speak. Please begin by stating your name and address for the record before you talk about your concerns. BSR has a dedicated phone line and email for statements to be read into the record. No statements were received.”

There were no comments, so the floor was closed.

V. Review/Approve Agenda

All

The Subcommittee reviewed the agenda and because of the urgency of the ADAP items requested items #8 - #11 be deferred.

Motion to accept the agenda but defer items #8 - #11.

Moved: Dr. Lawrence Friedman

Seconded: Dr. Javier Romero

Motion: Passed

VI. Review/Approve Minutes of November 21, 2025

All

Members reviewed the minutes of November 21, 2025, and Dr. Romero noted the sentence on page 4 “The head of household letter... ACA program” should be stricken since it is incorrect.

Motion to accept the minutes of November 21, 2025, with the corrections discussed.

Moved: Cristhian Ysea

Seconded: Dr. Javier Romero

Motion: Passed

VII. Reports

▪ **Ryan White Program**

Carla Valle-Schwenk

Carla Valle-Schwenk indicated the latest Ryan White expenditure and clients served reports are posted online and in the meeting materials.

▪ **Vacancy Report**

Marlen Meizoso

Marlen Meizoso indicated the January 2026 vacancy report was posted online and in the meeting materials.

VIII. Special Discussion

All

▪ **2026 Changes to ADAP and Impact**

Meeting materials included an email sent by the Dr. Choe at the Florida Department of Health regarding the changes to ADAP, detailing the removal of ACA premium support, moving to direct dispense only, capping FPL at 130%, and formulary changes removing Biktarvy and restricting Descovy.

Clients were only advised of the changes to the ADAP program if they consented to contact by mail. Letters were sent by the Department of Health in English only. No formal notice has been given nor was any shared with the statewide planning groups, no community groups were engaged, nor are any questions being answered.

While Florida is only being affected at this time, other states such as Texas, Alabama, and Indiana are taking note. ADAP clients in Miami-Dade comprise 25% of the total state program. The Health Resource Service Administration (HRSA) has not been responsive, but local legislators have been approached.

It is important that upcoming changes be shared with clients so they can try to get a three-month supply of medication, when available.

Conversations are being held with pharmaceutical companies and AIDS United has advocated via letter to the Florida Surgeon General about the changes.

While the Miami-Dade HIV/AIDS Partnership and its committees can't lobby, private citizens can share their concerns.

Dan Wall shared some preliminary analysis on the potential impact of the ADAP program changes. Annual medication cost for clients in ADAP is roughly \$21,840 per person for direct dispense. Under the Affordable Care Act (ACA) Insurance Premium support from ADAP, payments total over \$53 million dollars. The potential impact to the Ryan White Part A/MAI program for clients transitioning back into outpatient/ambulatory health is over \$6 million dollars, and over \$77 million for prescription drug assistance for those clients using direct dispense. This does not include the additional \$33.1 million for those ACA clients who no longer will have ACA covered prescription coverage. Overall, absorbing all ACA clients into RWP outpatient medical care and providing prescription drugs for all clients over 130% of FPL is not financially feasible. Various options are being explored to mitigate the impact including changing formularies, reducing eligibility, placing financial caps, and no longer funding select services. Programs with 340B/330B designated funding could use some of their funding to assist clients at their agencies.

The Part B program currently funds EFA providing food vouchers, and money is always returned to the state. The Partnership could request that other services be covered to assist with shortfalls.

Additionally, Minority AIDS Initiative funding is underutilized and improvements to usage are necessary for those categories it funds.

Ending the HIV Epidemic funding can't be used to fill the gap in services.

The Local AIDS Pharmaceutical Program (LPAP) is not intended for short term usage.

The Subcommittee agreed that the first step in the contingency development to address the changes to the ADAP program is to scale back services. Several options were discussed to reduce costs, and areas of potential cost savings were highlighted, including:

- Reducing the RWP Part A/MAI FPL eligibility threshold from 400% to 350% (estimate 1,100 clients);
- Review medical procedures for cost savings and restricting possible conditions, such as podiatry and ophthalmology.
- Eliminating health insurance for one year while logistics and financials are reviewed;
- Scaling back diagnostic testing;
- Reduced the number of substance abuse residential days from current total of 180;

- Find efficiencies under medical case management;
- Reassesses EFA coverage restrictions to Test and Treat;
- Use patient assistance programs (PAP) for medications;
- Under oral health care, removing specialty procedures or restricting procedures to basic care similar to the Medicaid program;
- Under medical transportation, removing rideshares such as Lyft and Uber;
- Eliminating food bank since there are food pantries in the community;
- Reduce some medications on the formulary;
- Eliminate outreach;
- Use Part B funding (\$1.6 million) to cover selected services

Motion to extend the meeting by 5 minutes.

Moved: Juliet Miller

Seconded: Dr. Javier Romero

Motion: Passed

The Subcommittee would like the Care and Treatment Committee to consider the following: reductions to food bank and oral health, including possible oral health formulary changes, find efficiencies and reduce medical case management spending, reduce the number of substance abuse residential days, eliminate ride share (Uber/Lyft) from medical transportation, reduce the FPL threshold for RWP eligibility, consider tweaks to the allowable conditions list for outpatient ambulatory services, and consider reductions to the formulary. These cost savings hopefully will create additional funding to support outpatient ambulatory health services. Additional assistance would be needed for medications which hopefully the Part B program or LPAPs can help with.

The Subcommittee requested to meet again on February 6, 2026, to continue to address the issues which will include the oral health care codes, allowable conditions list, and ADAP formulary.

IX. Announcements and Open Discussion

All

Dan Wall advised individuals to contact their legislators and speak their mind.

No additional announcements or open discussion items were made.

X. Next Meeting

Cristhian Ysea

The next meeting will be scheduled for Friday, February 6, 2026, in this room at 9:30 a.m. and the regularly scheduled Subcommittee meeting is scheduled for Friday, February 27, 2026, at 9:30 a.m. at BSR.

XI. Adjournment

James Dougherty

Mr. Dougherty thanked everyone for participating in the meeting and called for a motion to adjourn.

Motion to adjourn.

Moved: Yendi Serrano-Irizarry

Seconded: Cristhian Ysea

Motion: Passed

The meeting adjourned at 11:34 a.m.



Medical Care Subcommittee
Friday, February 6, 2026
9:30 a.m. – 11:30 a.m.
Behavioral Science Research
2121 Ponce de Leon Blvd., Ste. 240
Miami, FL 33134

AGENDA

- | | | |
|-------|--|-----------------|
| I. | Call to Order | James Dougherty |
| II. | Introductions | All |
| III. | Meeting Housekeeping | James Dougherty |
| IV. | Floor Open to the Public | Cristhian Ysea |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 23, 2026 | All |
| VII. | Standing Business | |
| | • Response to the 2026 ADAP Program Changes- Updates | All |
| | • Formulary Reviews and Prioritization | All |
| | ○ Oral Health Formulary | |
| | ○ Prescription Drugs Formulary | |
| | ○ Allowable Conditions | |
| VIII. | Announcements | All |
| IX. | Next Meeting: February 27, 2026 at BSR | Cristhian Ysea |
| X. | Adjournment | James Dougherty |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



Partnership Report to Committees and Subcommittee February 2, 2026, Meeting

Supporting documents related to motions in this report are available online at www.partnershipmiami.org/the-partnership-2/, or from Behavioral Science Research Corp. (BSR) staff. For more information, please contact mdcpartnership@behavioralscience.com.

Officer nominations were announced, members heard regular reports, and the below motions were approved.

Community Coalition Roundtable

1. Motion to recommend to Mayor Daniella Levine Cava the appointment of Rolando Hallmon to the Miami-Dade HIV/AIDS Partnership for a Representative of the Affected Community seat, and the appointment of James Riley to the Miami-Dade HIV/AIDS Partnership for the Mental Health Provider Representative seat.

Care and Treatment Committee

2. Motion to nominate Dr. Diego Shmuels as the Florida Comprehensive Planning Network alternate member.

These motions were approved in response to pending changes to ADAP funding:

3. Motion to grant the Recipient the discretion to provide a phased approach to funding changes in response to pending ADAP implementation of programmatic changes.
4. Motion to reduce the Federal Poverty Level eligibility from 400% to 350% for the Ryan White Part A and Minority AIDS Initiative (MAI) Program.
5. Motion to reduce the maximum annual allowance of the Part A Substance Abuse Residential days from 180 to 120 days.
6. Motion to remove ride share services from the Part A Medical Transportation service.
7. Motion to cut the Part A Oral Health Care service allocation in half and to allow the Medical Care Subcommittee to provide input on priorities and reduced services included in the Oral Healthcare Formulary.
8. Motion to eliminate the Part A Health Insurance Premium and Cost Sharing for Low-Income Individuals allocation.
9. Motion to eliminate the Part A Outreach allocation.
10. Motion to reduce the Part A Food Bank allocation to \$500,000.
11. Motion to reduce the Part A Medical Case Management allocation to \$3.5 million.
12. Motion to reduce the Part A Legal Services allocation to \$25,000.
13. Motion to remove the allocation for MAI Outreach.

14. Motion to remove ride share services from the MAI Medical Transportation service.
 15. Motion to defer the approval of the Psychosocial Support Services and Outreach service descriptions as presented and to review further updates in the future when the services are being provided.
-



Medical Care Subcommittee
Friday, February 6, 2026
9:30 a.m. – 11:30 a.m.
Behavioral Science Research
2121 Ponce de Leon Blvd., Ste. 240
Miami, FL 33134

AGENDA

- | | | |
|-------|--|-----------------|
| I. | Call to Order | James Dougherty |
| II. | Introductions | All |
| III. | Meeting Housekeeping | James Dougherty |
| IV. | Floor Open to the Public | Cristhian Ysea |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 23, 2026 | All |
| VII. | Standing Business | |
| | • Response to the 2026 ADAP Program Changes- Updates | All |
| | • Formulary Reviews and Prioritization | All |
| | ○ Oral Health Formulary | |
| | ○ Prescription Drugs Formulary | |
| | ○ Allowable Conditions | |
| VIII. | Announcements | All |
| IX. | Next Meeting: February 27, 2026 at BSR | Cristhian Ysea |
| X. | Adjournment | James Dougherty |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

Miami-Dade County Ryan White Program Oral Health Care

Summary of Available Dental Care Procedures

The following is a list of dental services available through the local Ryan White Program. Several limitations and restrictions apply; and the Ryan White Program must always be used as the payer of last resort. Please see below and contact your Oral Health Care team (dentist, medical case manager, etc.) for more details:

- **Diagnostics:**

- **Clinical Oral Evaluations**

- [dental exams; review of tooth, teeth, or mouth by a dentist]*

- Periodic
 - Limited
 - Comprehensive – oral and periodontal
 - Detailed and extensive

- **Imaging**

- [pictures of teeth from different views, using different equipment]*

- X-rays
 - Panoramic

- **Preventive:**

- **Dental Prophylaxis**

- [basic cleanings including brushing, flossing, scrubbing, and polishing teeth]*

- Dental cleanings

- **Topical fluoride treatment**

- [medicine applied to teeth to make them stronger]*

- **Other preventive services**

- Oral hygiene instructions
 - *[instructions on how to brush, floss, and keep teeth healthy]*
 - Sealants
 - *[coating painted into grooves of adult teeth to prevent cavities]*
 - Nutritional counseling
 - Tobacco prevention and cessation counseling

Miami-Dade County Ryan White Program Oral Health Care

Summary of Available Dental Care Procedures

- **Restorative:**

[dental services to fix or repair teeth]

- Amalgam (fillings)
- Resin-based composites
- Crowns
- Re-cementing / re-bonding
- Protective restoration
- Core buildup
- Pin retention
- Post and core

- **Endodontics:**

[dental services to fix the inside part of a tooth (nerve); including, but not limited to, root canals]

- Pulpotomy
 - Removal
 - Debridement
 - Endodontic Therapy
- Apicoectomy

- **Periodontics:**

[deep cleanings that may involve both teeth and gums]

- Surgical Services
 - Gingivectomy
 - Gingivoplasty
 - Gingival flap
 - Crown lengthening
 - Osseous surgery
 - Autogenous connective tissue graft
 - Free soft tissue graft
- Non-Surgical Periodontal Services
 - Coronal splints (intra-coronal and extra-coronal)
 - Periodontal scaling and root planing
 - Scaling for gingival inflammation
 - Debridement
- Other Periodontal Services
 - Periodontal maintenance

Miami-Dade County Ryan White Program Oral Health Care

Summary of Available Dental Care Procedures

- **Prosthodontics, removable:**
[dentures or other objects to replace teeth; removable]
 - Dentures
 - Complete
 - Immediate
 - Partial
 - Interim
 - Adjustments
 - Repairs
 - Rebase
 - Reline
 - Tissue conditioning
 - Precision attachment

- **Prosthodontics, fixed:**
[dentures or other objects to replace teeth; not removable]
 - Fixed partial denture pontics
 - Fused to high noble metal
 - Fused to predominantly base metal
 - Porcelain / ceramic
 - Resin

 - Fixed partial denture retainers
 - Inlays / onlays
 - Crowns

 - Other fixed partial denture services
 - Re-cement or re-bond

- **Maxillofacial Prosthetics:**
 - Fluoride gel carrier (fluoride applicator)

Miami-Dade County Ryan White Program Oral Health Care

Summary of Available Dental Care Procedures

- **Implant Services:**

[MIAMI-DADE COUNTY RYAN WHITE PROGRAM RESTRICTIONS: LIMITED SERVICES – UNITS AND CLIENT ELIGIBILITY; NOT FOR COSMETIC PURPOSES; A LETTER OF MEDICAL NECESSITY FROM CLIENT'S DENTIST IS REQUIRED]

- Surgical Services
 - Surgical placement
 - Surgical access
 - Surgical removal
 - Single crowns
 - Abutment supported
 - Implant supported
 - Fixed partial denture retainer
 - Abutment supported
 - Implant supported
- Other Implant Services
 - Repair implant abutment
- Implant / Abutment Supported Removable Dentures
 - Implant / abutment supported removal denture for edentulous arch
 - Semi-precision abutment / attachment – placement

- **Oral and Maxillofacial Surgery:**

[covered under the Oral Health Care service category only]

- Extractions
 - *[tooth removal; including anesthesia, suturing, and post-op care]*
- Other surgical procedures
 - Tooth re-implantation and / or stabilization
- Alveoloplasty
- Excision of lesions
 - Removal of:
 - Soft tissue lesions
 - Intra-osseous lesions
- Excision of bone tissue
 - Removal of:
 - Lateral exostosis
 - Torus palatinus
 - Toris mandibularis

Miami-Dade County Ryan White Program Oral Health Care

Summary of Available Dental Care Procedures

- Surgical incision
 - Incision and drainage of abscess
 - Removal of foreign body
 - Partial ostectomy / sequestrectomy
- Repair traumatic wounds
 - Suturing (small; complicated)
- Other repair procedures
 - Excision of hyperplastic tissue
- **Adjunctive General Services:**
[additional dental services combined with other procedures, where appropriate]
 - Unclassified treatment
 - Fixed partial denture sectioning
 - Anesthesia
 - Local anesthesia (with operative or surgical procedure)
 - Deep sedation / general anesthesia
 - Inhalation of nitrous oxide / analgesia, anxiolysis
 - Intravenous moderate (conscious) sedation
 - Professional consultation
 - Consultation by dentist or physician other than the requesting dentist or physician
 - Miscellaneous
 - Desensitizing medicament
 - Treatment of complications (post-surgical) – unusual
 - Occlusal guard
[night guard, mouth guard, bite guard]
 - Hard (full and partial)
 - Soft (full and partial)
 - Occlusal adjustment

NOTE: Ryan White Program-funded dental providers, billing staff, and medical case managers have been provided with a detailed Miami-Dade County Oral Health Care Formulary (including categories of service, dental procedure codes, nomenclature, descriptions found in the Current Dental Terminology book from the American Dental Association; along with guidance on local limitations). Due to copyright restrictions on the terminology, descriptions, and procedure codes, copies of the Miami-Dade County's detailed formulary will be provided upon request to authorized persons, as appropriate.

Requested Prioritization of OHC Services
From Former OHC Workgroup Member

Priority Ranking	Category	Comment
1	Diagnostics	Diagnostics are the most important, both exams and x-rays. This is the foundation to all care.
2	Preventive	Prevents/reduces progression of dental disease. As for nutrition and tobacco prevention, this is discussed with patients as needed but rarely or never bill for this at our center.
3	Oral surgery	Extractions are necessary to eliminate/reduce infection, pain, non-restorable teeth.
4	Restorative	The repair of existing teeth. Stops caries from progressing.
5	Periodontics	Scaling and root planing (deep cleanings) important in managing gum disease and controlling bone loss. Very important for our HIV+ patients, diabetics, CVD.
6	Endodontics	Helps to preserve a natural tooth that will otherwise need to be extracted. Pulpotomy important for immediate pain relief. We do not do apicoectomy at our center. Usually performed by endodontist.
7	Removable and Fixed Prostho	Dentures important for tooth replacement, helps mastication, eating properly, nutrition, speech, facial form. Crowns and bridges are important to maintain tooth structure and tooth replacement.
8	Adjunctive General Services- Occlusal Guard	In this section, the main procedure that applies to our center is occlusal guards.
9	Implants	No Comment. Not done at our center.

Expanded Benefits (Services that are covered in addition to your current benefits) Contact the plan for benefit limits

<http://www.libertydentalplan.com/>
[FL Medicaid](https://www.flmedicaid.com/) Liberty Dental
[DentaQuest](https://www.dentaquest.com/)

Contact and Plan Information		✓	✓
Plan Report Cards	Click here to view Plan Report Cards (https://www.floridahealthfinder.gov/HealthPlans/Search.aspx?p=5)		
Expanded Benefits for All Ages			
Hydroxyapatite (Calcium) Application			✓
Over-the-Counter Products	✓		✓
Expanded Benefits for Ages 20 and Under			
Nutritional and Tobacco Cessation Counseling	✓		
Surgical Placement and Maintenance of Implant Body, Abutment and Crown			✓
Expanded Benefits for Ages 21 and Over			
Adjunctive Dental Services – Treatment of Complications			✓
Amalgam Restorations (Dental Fillings)	✓		✓
Cavity Medicament	✓		✓
Debridement (Removal of Damaged Tissue or Foreign Objects)	✓		✓
Diabetes Testing	✓		
Diagnostic X-Rays	✓		✓
Oral Hygiene Instruction	✓		✓
Oral Screenings and Evaluation	✓		✓
Periodontal Maintenance			✓
Periodontal Scaling	✓		✓
Prophylaxis (Cleaning Treatment)	✓		✓
Sealants	✓		✓
Topical Fluoride and Fluoride Varnish	✓		✓
Expanded Benefits for Seniors Ages 65 AND Older			
Crowns – Porcelain Ceramic and Resin Based			✓
Crowns – Stainless Steel (Pre-Fabricated)	✓		
Endodontic Therapies, including Root Canals (Anterior, Premolar, Molar)			✓
Therapeutic Parenteral Drugs			✓
Expanded Benefits for Individuals with Developmental Disabilities			
Acclimation Visits	✓		✓
Adjunctive Dental Services – Behavioral Management			✓
Adjunctive Dental Services – Denture Cleaning and Inspections			✓
Crowns – Porcelain Ceramic and Resin-Based			✓

Crowns – Stainless Steel (Pre-Fabricated)	✓	
Endodontic Therapies, including Root Canals (Anterior, Premolar, Molar)		✓
Prophylaxis (Extra Cleanings)	✓	✓
Expanded Benefits for Pregnant Women		
Periodontal Maintenance		✓
Prophylaxis (Extra Cleanings)	✓	✓

Dental Plan Contact Information

Liberty Dental Phone: 1-833-276-0850 TDD: 1-877-855-8039 Website: http://www.libertydentalplan.com/FLMedicaid (http://www.libertydentalplan.com/FLMedicaid)	DentaQuest Phone: 1-888-468-5509 TDD: 1-800-466-7566 Website: https://www.dentaquest.com (https://www.dentaquest.com)
--	--

Contact Us

Have questions? We can help. Choice Counselors are available at **1-877-711-3662** (tel:1-877-711-3662) to answer your questions M-TH 8am-8pm, F 8am-7pm.

 Agency for Health Care Administration

 P.O. Box 5197, MS 62 Tallahassee, FL 32314

 Report Medicaid Fraud (http://ahca.myflorida.com/Executive/Inspector_General/complaints.shtml)

 Text: **357662**

 TDD: **1-866-467-4970** (tel:1-866-467-4970)

 File a Complaint (/complaint/)

 Authorized Rep. Form (https://ffiles2.blob.core.windows.net/public/english/Designation%20of%20Authorized%20Representative%20For%20Selection%20of%20Managed%20Care%20Plan_EN.pdf)

 Contact Us (/home/contact)

 Translation Services (/translationservices)

 SMS (/sms)

 Privacy (/privacy)

Health Plans

 Health Plans and Program (/health/comparehealthplans)

 Before Choosing a Health Plan (/health/howtochooseaplan)

 Enrolling in a Health Plan (/health/enroll)

 MMA Pre-eligibility Plan Choice (/health/express)

 Plan Phone Numbers (/home/planphonenumber)

Dental Plans

 Dental Plans and Program (/dental/dentalplaninformation)

 Before Choosing a Dental Plan (/dental/howtochooseaplan)

 Enrolling in a Dental Plan (/dental/enroll)

 Dental Pre-eligibility Plan Choice (/dental/express)

 Plan Phone Numbers (/home/planphonenumber)

Information

 Glossary (/home/glossary)

 FAQ (/home/faq)

 Agency Phone Numbers (/home/agencyphonenumber)

 Letters And Brochures (/home/lettersandbrochures)

 Medicaid Fair Hearing (/home/medicaidfairhearing)

 FL Medicaid Member Portal (<https://members.flmedicaidmanagedcare.com/login?langCd=en>)



Medical Care Subcommittee
Friday, February 6, 2026
9:30 a.m. – 11:30 a.m.
Behavioral Science Research
2121 Ponce de Leon Blvd., Ste. 240
Miami, FL 33134

AGENDA

- | | | |
|-------|--|-----------------|
| I. | Call to Order | James Dougherty |
| II. | Introductions | All |
| III. | Meeting Housekeeping | James Dougherty |
| IV. | Floor Open to the Public | Cristhian Ysea |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 23, 2026 | All |
| VII. | Standing Business | |
| | • Response to the 2026 ADAP Program Changes- Updates | All |
| | • Formulary Reviews and Prioritization | All |
| | ○ Oral Health Formulary | |
| | ○ Prescription Drugs Formulary | |
| | ○ Allowable Conditions | |
| VIII. | Announcements | All |
| IX. | Next Meeting: February 27, 2026 at BSR | Cristhian Ysea |
| X. | Adjournment | James Dougherty |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024			
****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****			
CS indicates controlled substance. PA indicates prior authorization required.			
Generic Name	Brand Name (listed for Antiretroviral drugs only)	Therapeutic Classification	Pharmacologic Classification
abacavir	Ziagen	Antiretroviral	NRTI
abacavir / lamivudine	Epzicom	Antiretroviral	NRTI combo
abacavir / dolutegravir / lamivudine	Triumeq	Antiretroviral	INSTI/NRTI combo
atazanavir	Reyataz	Antiretroviral	PI
atazanavir/cobicistat	Evotaz	Antiretroviral	PI/PK Enhancer
bictegravir / emtricitabine / tenofovir alafenamide	Biktarvy	Antiretroviral	INSTI/NRTI combo
cabotegravir	Vocabria	Antiretroviral	INSTI
cabotegravir / rilpivirine	Cabenuva	Antiretroviral	INSTI/NNRTI combo
cobicistat	Tybost	Antiretroviral	PK Enhancer
darunavir	Prezista	Antiretroviral	PI
darunavir / cobicistat	Prezcobix	Antiretroviral	PI/PK Enhancer
darunavir / cobicistat / emtricitabine / tenofovir alafenamide	Symtuza	Antiretroviral	PI/NRTI combo
dolutegravir	Tivicay	Antiretroviral	INSTI
dolutegravir / lamivudine	Dovato	Antiretroviral	INSTI/NRTI combo
dolutegravir / rilpivirine	Juluca	Antiretroviral	INSTI/NNRTI combo
doravirine	Pifeltro	Antiretroviral	NNRTI
doravirine / lamivudine / tenofovir disoproxil fumarate	Delstrigo	Antiretroviral	NNRTI/NRTI combo
efavirenz	Sustiva	Antiretroviral	NNRTI
efavirenz / emtricitabine / tenofovir disoproxil fumarate	N/A	Antiretroviral	NNRTI/NRTI combo
efavirenz / lamivudine / tenofovir disoproxil fumarate	Symfi, SymfiLo	Antiretroviral	NNRTI/NRTI combo
elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide	Genvoya	Antiretroviral	INSTI/NRTI combo
elvitegravir / cobicistat / emtricitabine /tenofovir disoproxil fumarate	Stribild	Antiretroviral	INSTI/NRTI combo
emtricitabine	Emtriva	Antiretroviral	NRTI
emtricitabine / tenofovir alafenamide	Descovy	Antiretroviral	NRTI combo
emtricitabine / tenofovir disoproxil fumarate	Truvada	Antiretroviral	NRTI combo
enfuvirtide	Fuzeon	Antiretroviral	Fusion inhibitor
etravirine	Intelence	Antiretroviral	NNRTI
fostemsavir	Rukobia	Antiretroviral	Gp-120 directed attachment inhibitor
ibalizumab-uiyk injection ^{PA}	Trogarzo ^{PA}	Antiretroviral	CD4 post-attachment HIV-1 inhibitor
lamivudine	Epivir	Antiretroviral	NRTI
lamivudine / zidovudine	Combivir	Antiretroviral	NRTI combo
lenacapavir	Sunlenca	Antiretroviral	Capsid inhibitor
lopinavir / ritonavir	Kaletra	Antiretroviral	PI/PK Enhancer
maraviroc	Selzentry	Antiretroviral	CCR5 antagonist
nevirapine, nevirapine XR	Viramune, Viramune XR	Antiretroviral	NNRTI
raltegravir, raltegravir HD	Isentress, Isentress HD	Antiretroviral	INSTI
rilpivirine	Edurant	Antiretroviral	NNRTI
rilpivirine / emtricitabine/ tenofovir disoproxil fumarate	Complera	Antiretroviral	NNRTI/NRTI combo
rilpivirine / emtricitabine / tenofovir alafenamide	Odefsey	Antiretroviral	NNRTI/NRTI combo
ritonavir	Norvir	Antiretroviral	PK Enhancer
tenofovir alafenamide	Vemlidy	Antiretroviral	NRTI
tenofovir disoproxil fumarate	Viread	Antiretroviral	NRTI

INSTI = Integrase Strand Transfer Inhibitor, NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor, NRTI = Nucleoside/Nucleotide Reverse Transcriptase Inhibitor, PK= Pharmokinetic, PI = Protease Inhibitor

tenofovir disoproxil fumarate / lamivudine	Cimduo, Temixys	Antiretroviral	NRTI combo
zidovudine	Retrovir	Antiretroviral	NRTI
Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024 ****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.**** ^{CS} indicates controlled substance. ^{PA} indicates prior authorization required.			
Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
acetaminophen	Analgesic	Non-salicylate analgesic	capsule, tablet, oral liquid, rectal suppository
acetaminophen/hydrocodone ^{CS}	Analgesic	Nonsalicylate/opioid	capsule, tablet, oral liquid
acetaminophen/oxycodone ^{CS}	Analgesic	Nonsalicylate/opioid	tablet, oral liquid
acetazolamide	Antiglaucoma	Carbonic anhydrase inhibitor	capsule, tablet
acyclovir	Anti-infective	Antiviral	capsule, tablet, oral liquid, topical
albuterol	Respiratory	Beta-2 Agonist	inhaler, nebulizer solution, tablet, oral liquid
albuterol HFA	Respiratory	Beta-2 Agonist	inhaler
albuterol/ipratropium	Respiratory	Anticholinergic + Beta-2 Agonist, oral inhaled	inhaler, nebulizer solution
alendronate	Osteoporosis	Bisphosphonate	tablet, oral liquid
alirocumab	Cardiovascular, antihyperlipidemic	PCSK9 inhibitor	injection
allopurinol	Antigout	Xanthine oxidase inhibitor	tablet
amitriptyline	Central nervous system, antidepressant	Tricyclic antidepressant (TCA)	tablet
amlodipine	Cardiovascular	Calcium channel blocker	tablet, oral liquid
amlodipine/atorvastatin	Cardiovascular	Calcium channel blocker/HMG-CoA reductase inhibitor	tablet
amlodipine/benazepril	Cardiovascular	Calcium channel blocker/ACE inhibitor	capsule
amlodipine/olmesartan	Cardiovascular, antihypertensive	Calcium channel blocker/angiotensin II receptor blocker	tablet
amlodipine/valsartan	Cardiovascular, antihypertensive	Calcium channel blocker/angiotensin II receptor blocker	tablet
ammonium lactate	Dermatologic	Humectant	topical
amoxicillin	Anti-infective	Beta-lactam antibiotic	capsule, tablet, oral liquid
amoxicillin/clavulanate	Anti-infective	Beta-lactam antibiotic/beta-lactamase inhibitor	tablet, oral liquid
amphetamine/dextroamphetamine ^{CS}	Central nervous system	ADHD agent, stimulant	tablet, capsule
apixaban	Blood formation and coagulation	Anticoagulant	tablet
aripiprazole	Central nervous system	Antipsychotic, atypical	tablet, injection
aspirin	Analgesic	Salicylate	caplet, tablet, rectal suppository
atenolol	Cardiovascular	Beta-blocker	tablet
atenolol/chlorthalidone	Cardiovascular	Beta-blocker/thiazide-like diuretic	tablet
atomoxetine	Central nervous system	ADHD agent, non-stimulant	capsule
atorvastatin	Cardiovascular, antihyperlipidemic	HMG-CoA reductase inhibitor	tablet, oral liquid
atovaquone	Anti-infective	Amebicide	oral liquid
azelastine	Respiratory	Antihistamine	nasal spray, eye drops
azelastine/fluticasone	Respiratory	Antihistamine/corticosteroid, intranasal	nasal spray
azithromycin	Anti-infective	Macrolide antibiotic	tablet, oral liquid, eye drops
baclofen	Central nervous system	Muscle relaxant	tablet, oral liquid
baloxavir	Anti-infective	Anti-influenza antiviral	tablet, oral liquid
beclomethasone	Respiratory	Corticosteroid	nasal spray, inhaler
bempedoic acid	Cardiovascular, antihyperlipidemic	ACL inhibitor	tablet
benazepril	Cardiovascular	Angiotensin converting enzyme (ACE) inhibitor	tablet
benazepril/hydrochlorothiazide	Cardiovascular	ACE inhibitor/ thiazide diuretic	tablet

Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024			
****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****			
CS indicates controlled substance. PA indicates prior authorization required.			
Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
benzoyl peroxide	Dermatologic	Antibiotic + keratolytic	topical
benzoyl peroxide/clindamycin	Dermatologic	Anti-acne retinoid	topical
benztropine	Central nervous system	Anticholinergic	tablet
betamethasone dipropionate	Dermatologic	Corticosteroid	topical
betamethasone valerate	Dermatologic	Corticosteroid	topical
betamethasone/clotrimazole	Dermatologic	Corticosteroid, antifungal	topical
bisacodyl	Gastrointestinal	Laxative, stimulant	tablet, rectal suppository
bismuth subcitrate potassium/metronidazole/tetracycline	Gastrointestinal	Helicobacter pylori agents	tablets and capsules (therapy kit)
brexpiprazole	Central nervous system	Antipsychotic, atypical	tablet
brimonidine	Antiglaucoma	Alpha-2 agonist	eye drops, eye gel
brimonidine/timolol	Antiglaucoma	Alpha agonist/beta blocker	eye drops
budesonide	Respiratory	Corticosteroid	inhaler, nasal spray
budesonide/formoterol	Respiratory	Corticosteroid + Long acting Beta-2 Agonist, oral inhaled	inhaler
budesonide/glycopyrrolate/formoterol	Respiratory	Corticosteroid/anticholinergic/long-acting Beta-2 agonist	inhaler
buprenorphine/naloxone ^{CS}	Substance abuse	Opiate agonist/antagonist	tablet, oral film
buprenorphine ^{CS}	Substance abuse	Opiate agonist/antagonist	tablet, oral film, patch
bupropion	Central nervous system	Antidepressant-miscellaneous, aminoketone	tablet
buspirone	Central nervous system	Anxiolytic	tablet
calcium carbonate	Vitamin	Vitamin	tablet, oral liquid
calcium with vitamin D	Vitamin	Vitamin	tablet
canagliflozin	Antidiabetic	Sodium-glucose co-transporter 2 (SGLT2) inhibitor	tablet
canagliflozin/metformin	Antidiabetic	SGLT2 inhibitor/biguanide	tablet
capsaicin	Dermatologic	Analgesic	topical
carbamazepine	Central nervous system	Anti-manic, anti-seizure	tablet, capsule
carbamide peroxide	Otic	Ear wax removal agent	ear drops, oral liquid
carboxymethylcellulose	Ophthalmic	Lubricating agent	eye drops
carvedilol	Cardiovascular	Beta-blocker	capsule, tablet
cefdinir	Anti-infective	Cephalosporin antibiotic	capsule, oral liquid
cefixime	Anti-infective	Cephalosporin antibiotic	capsule, tablet, oral liquid
ceftriaxone	Anti-infective	Cephalosporin antibiotic	injection
celecoxib	Analgesic	COX-II Inhibitor Non-steroidal anti-inflammatory drug	capsule, oral liquid
cephalexin	Anti-infective	Cephalosporin antibiotic	capsule, tablet, oral liquid
cetirizine	Respiratory	Antihistamine	tablet, oral liquid
chlorhexidine gluconate (0.12%)	Dermatologic	Anti-infective	oral liquid
chlorthalidone	Cardiovascular	Thiazide-like diuretic	tablet
cholecalciferol (vitamin D3)	Vitamin	Vitamin	capsule, tablet, oral liquid
ciprofloxacin	Anti-infective	Quinolone antibiotic	tablet, ear drops, eye drops, oral liquid
ciprofloxacin/dexamethasone	Anti-infective/anti-inflammatory	Quinolone antibiotic/corticosteroid	ear drops
citalopram	Central nervous system, antidepressant	Selective serotonin reuptake inhibitor (SSRI)	capsule, tablet, oral liquid
clarithromycin	Anti-infective	Macrolide antibiotic	tablet, oral liquid
clindamycin	Anti-infective	Lincosamide antibiotic	capsule, oral liquid, topical
clonazepam ^{CS}	Central nervous system	Benzodiazepine	tablet

Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024			
****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****			
CS indicates controlled substance. PA indicates prior authorization required.			
Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
clonidine	Cardiovascular	Centrally acting alpha 2 agonist	tablet, oral liquid, patch
clopidogrel	Cardiovascular	Platelet inhibitor	tablet
clotrimazole	Anti-infective	Azole antifungal	oral troche, topical
conjugated estrogens (topical only)	Dermatologic	Estrogen	topical
crofelemer	Gastrointestinal	Antidiarrheal	tablet
cyanocobalamin (vitamin B12)	Vitamin	Vitamin	tablet, oral liquid, nasal spray, injection
cyclobenzaprine	Central nervous system	Muscle relaxant	capsule, tablet
cyproheptadine	Respiratory	Antihistamine	tablet, oral liquid
dabigatran	Blood formation and coagulation	Anticoagulant	capsule, oral granules
dapagliflozin	Antidiabetic	Sodium-glucose co-transporter 2 (SGLT2) inhibitor	tablet
dapagliflozin/metformin	Antidiabetic	SGLT2 inhibitor/biguanide	tablet
dapsone	Anti-infective	Sulfone antibiotic	tablet, topical
dexamethasone/neomycin/polymyxin b	Ophthalmic	Corticosteroid/antibacterial	eye drops, eye ointment
dextromethorphan/promethazine	Respiratory	Antitussive/antihistamine	oral liquid
diazepam ^{CS}	Central nervous system	Benzodiazepine	tablet, oral liquid, nasal spray, rectal gel
diclofenac	Analgesic	Non-steroidal anti-inflammatory drug	capsule, tablet, eye drops, topical
dicyclomine	Gastrointestinal	Antispasmodic	capsule, tablet, oral liquid
digoxin	Cardiovascular	Cardiac glycoside	tablet, oral liquid
diltiazem	Cardiovascular	Calcium channel blocker	capsule, tablet
diphenhydramine	Respiratory	Antihistamine	capsule, tablet, oral liquid, topical
diphenoxylate/atropine ^{CS}	Gastrointestinal	Antidiarrheal	tablet, oral liquid
disulfiram	Substance abuse	Alcohol deterrent	tablet
divalproex	Central nervous system	Anticonvulsant, mood stabilizer	capsule, tablet, oral liquid
docusate sodium	Gastrointestinal	Laxative, stool softener	capsule, tablet, oral liquid
donepezil	Central nervous system	Cholinesterase inhibitor	tablet, patch
dorzolamide	Antiglaucoma	Carbonic anhydrase inhibitor	eye drops
dorzolamide/ timolol	Antiglaucoma	Carbonic anhydrase inhibitor, beta-blocker	eye drops
doxazosin	Cardiovascular	Alpha-blocker	tablet
doxepin	Central nervous system	Tricyclic antidepressant (TCA)	capsule, tablet, oral solution, topical
doxycycline	Anti-infective	Tetracycline antibiotic	capsule, tablet, oral liquid
doxylamine/pyridoxine	Gastrointestinal	Anti-nausea agent	tablet
dronabinol ^{CS}	Gastrointestinal, appetite stimulant	Cannabinoid	capsule, oral liquid
dulaglutide	Antidiabetic	Glucagon-like peptide-1 receptor agonist (GLP-1 RA)	injection
duloxetine	Central nervous system, antidepressant	Serotonin-norepinephrine reuptake inhibitor	capsule
elbasvir/grazoprevir	Anti-infective	Hepatitis C antiviral	tablet
empagliflozin	Antidiabetic	Sodium-glucose co-transporter 2 (SGLT2) inhibitor	tablet
empagliflozin/metformin	Antidiabetic	SGLT2 inhibitor/biguanide	tablet
enalapril	Cardiovascular	Angiotensin converting enzyme (ACE) inhibitor	tablet, oral liquid
enalapril/hydrochlorothiazide	Cardiovascular	ACE inhibitor/ thiazide diuretic	tablet
entecavir	Anti-infective	Hepatitis B antiviral	tablet, oral liquid
epoetin alfa	Blood formation and coagulation	Erythropoiesis stimulating agent	injection

Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024			
****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****			
CS indicates controlled substance. PA indicates prior authorization required.			
Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
ergocalciferol (vitamin D2)	Vitamin	Vitamin	capsule, tablet, oral liquid
escitalopram	Central nervous system, antidepressant	Selective serotonin reuptake inhibitor (SSRI)	tablet, oral liquid
esomeprazole	Gastrointestinal	Proton pump inhibitor	capsule, tablet, oral powder
estradiol	Endocrine	Estrogen	tablet, topical, injection
ethambutol	Anti-infective	Antimycobacterial	tablet
ethinyl estradiol/desogestrel	Endocrine	Estrogen/Progestin	tablet
ethinyl estradiol/etonogestrel	Endocrine	Estrogen/Progestin	vaginal ring
ethinyl estradiol/levonorgestrel	Endocrine	Estrogen/progestin	tablet, patch
ethinyl estradiol/norethindrone	Endocrine	Estrogen/progestin	tablet
ethinyl estradiol/norethindrone/ferrous fumarate	Endocrine	Estrogen/progestin/iron	tablet
ethinyl estradiol/norgestimate	Endocrine	Estrogen/progestin	tablet
ethinyl estradiol/norgestrel	Endocrine	Estrogen/progestin	tablet
evolocumab	Cardiovascular, antihyperlipidemic	PCSK9 inhibitor	injection
ezetimibe	Cardiovascular, antihyperlipidemic	Cholesterol absorption inhibitor	tablet
ezetimibe/rosuvastatin	Cardiovascular, antihyperlipidemic	Cholinesterase inhibitor/HMG CoA reductase inhibitor	tablet
famciclovir	Anti-infective	Antiviral	tablet
famotidine	Gastrointestinal, acid reducing	Histamine 2 receptor blocker	tablet, oral powder
fenofibrate	Cardiovascular, antihyperlipidemic	Fibric acid derivative	capsule, tablet
ferrous sulfate	Vitamin	Vitamin	tablet, oral liquid
fexofenadine	Respiratory	Antihistamine	tablet, oral liquid
fidaxomicin	Anti-infective	Macrolide antibiotic	tablet, oral powder
filgrastim	Blood formation and coagulation	Granulocyte stimulating agent	injection
finasteride	Genitourinary	5-Alpha Reductase Inhibitor	tablet
fluconazole	Anti-infective	Azole antifungal	tablet, oral liquid
flunisolide (nasal spray)	Respiratory	Corticosteroid, nasal	nasal spray
fluoxetine	Central nervous system, antidepressant	Selective serotonin reuptake inhibitor (SSRI)	capsule, tablet, oral liquid
fluoxetine/olanzapine	Central nervous system	SSRI/atypical antipsychotic, antimanic	capsule
fluticasone	Respiratory	Corticosteroid	inhaler, nasal spray
fluticasone furoate/umeclidinium/vilanterol	Respiratory	Corticosteroid/long-acting muscarinic antagonist/long-acting Beta-2 agonist	inhaler
fluticasone/salmeterol	Respiratory	Corticosteroid + Long acting Beta-2 Agonist, oral inhaled	inhaler
fluticasone/vilanterol	Respiratory	Corticosteroid/long-acting Beta-2 agonist	inhaler
folic acid	Vitamin	Vitamin	capsule, tablet
formoterol	Respiratory	Long-acting Beta-2 agonist	inhaler, nebulizer solution
frovatriptan	Central nervous system	Antimigraine	tablet
furosemide	Cardiovascular	Loop diuretic	tablet, oral liquid
gabapentin	Central nervous system	Anticonvulsant, mood stabilizer	capsule, tablet
gemfibrozil	Cardiovascular, antihyperlipidemic	Fibric acid derivative	tablet
glecaprevir/pibrentasvir	Anti-infective	Hepatitis C antiviral	tablet, oral pellet packet
glimepiride	Antidiabetic	Sulfonylurea	tablet
glipizide	Antidiabetic	Sulfonylurea	tablet
glipizide/metformin	Antidiabetic	Sulfonylurea/biguanide	tablet

Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024			
****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****			
CS indicates controlled substance. PA indicates prior authorization required.			
Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
glyburide	Antidiabetic	Sulfonylurea	tablet
glyburide/metformin	Antidiabetic	Sulfonylureas/Biguanides	tablet
glycopyrrolate	Respiratory	Anticholinergic	tablet, oral liquid
hepatitis A adult vaccine	Vaccines	Viral vaccine	injection
hepatitis A/B vaccine	Vaccines	Viral vaccine	injection
hepatitis B adult vaccine	Vaccines	Viral vaccine	injection
hepatitis B vaccine (recombinant, adjuvanted)	Vaccines	Viral vaccine	injection
human papilloma virus vaccine (recombinant)	Vaccines	Viral vaccine	injection
hydralazine	Cardiovascular	Vasodilating agents	tablet
hydrochlorothiazide	Cardiovascular	Thiazide diuretic	capsule, tablet
hydrocortisone	Anti-inflammatory	Corticosteroid	topical, tablet, enema
hydrocortisone/neomycin/polymyxin b	Anti-inflammatory/anti-infective	Corticosteroid/antibacterial	ear drops
hydrocortisone/pramoxine	Anti-inflammatory/anesthetic	Corticosteroid/anesthetic	topical
hydroxyzine	Respiratory or CNS	Antihistamine or anxiolytic	capsule, tablet, oral liquid
hyoscyamine	Gastrointestinal	Antispasmodic	tablet oral liquid
ibuprofen	Analgesic	Nonsteroidal anti-inflammatory drug	capsule, tablet, oral liquid
imiquimod	Dermatologic	Immune response modifier	topical
influenza vaccine (including high dose)	Vaccines	Viral vaccine	injection
inhaler spacer (one time only)	Respiratory	Inhaler spacer device	spacer device
insulin aspart	Antidiabetic	Insulin-rapid acting	injection
insulin degludec	Antidiabetic	Insulin	injection
insulin detemir	Antidiabetic	Insulin intermediate to long acting	injection
insulin glargine	Antidiabetic	Insulin-long acting	injection
insulin isophane (NPH)	Antidiabetic	Insulin-intermediate acting	injection
insulin lispro	Antidiabetic	Insulin-rapid acting	injection
insulin NPH and insulin regular	Antidiabetic	Insulin-70/30	injection
insulin regular	Antidiabetic	Insulin-short acting	injection
ipratropium	Respiratory	Anticholinergic	inhaler, nebulizer solution
irbesartan	Cardiovascular	Angiotensin II receptor blocker (ARB)	tablet
irbesartan/hydrochlorothiazide	Cardiovascular	ARB/ thiazide diuretic	tablet
isoniazid	Anti-infective	Antimycobacterial	tablet, oral liquid
isosorbide dinitrate	Cardiovascular	Vasodilating agents	tablet
isosorbide mononitrate	Cardiovascular	Vasodilating agents	tablet
itraconazole	Anti-infective	Azole antifungal	capsule, oral liquid
ivabradine	Cardiovascular	Hyperpolarization-activated cyclic nucleotide-gated channel blocker	tablet, oral liquid
ketoconazole	Anti-infective	Azole antifungal	tablet, topical
labetalol	Cardiovascular	Beta-blocker	tablet
lactulose	Gastrointestinal	Laxative, osmotic	oral liquid
lamotrigine	Central nervous system	Anticonvulsant, mood stabilizer	tablet, oral liquid
lanolin alcohol-mo-w.pet-ceres (Eucerin)	Emmolient	Moisturizer	topical
lansoprazole	Gastrointestinal	Proton pump inhibitor	capsule, tablet
lanthanum carbonate	Gastrointestinal	Phosphate binder	tablet

Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024			
****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****			
CS indicates controlled substance. PA indicates prior authorization required.			
Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
latanoprost	Antiglaucoma	Prostaglandin	eye drops
ledipasvir/sofosbuvir	Anti-infective	Hepatitis C antiviral	tablets, oral pellet packet
leucovorin	Vitamin	Vitamin	tablet
levetiracetam	Central nervous system	Anticonvulsant, mood stabilizer	tablet, oral liquid
levofloxacin	Anti-infective	Quinolone antibiotic	tablet, oral liquid
levonorgestrel	Endocrine	Progestin	tablet, intrauterine device
levothyroxine	Endocrine	Thyroid supplement	tablet
lidocaine	Anesthetic	Anesthetic	topical
linaclotide	Gastrointestinal	Irritable bowel syndrome agent	capsule
liothyronine	Endocrine	Thyroid supplement	tablet
liraglutide	Antidiabetic	Glucagon-like peptide-1 receptor agonist (GLP-1 RA)	injection
lisinopril	Cardiovascular	Angiotensin converting enzyme (ACE) inhibitor	tablet
lisinopril/hydrochlorothiazide	Cardiovascular	Angiotensin converting enzyme (ACE) inhibitor/ thiazide	tablet
lithium carbonate	Central nervous system	Mood stabilizer	capsule, tablet
loperamide	Gastrointestinal, antidiarrheal	Antidiarrheal	capsule, tablet, oral liquid
loratadine	Respiratory	Antihistamine	capsule, tablet, oral liquid
lorazepam ^{CS}	Central nervous system	Benzodiazepine	tablet, oral liquid
losartan	Cardiovascular	Angiotensin II receptor blocker (ARB)	tablet
losartan/hydrochlorothiazide	Cardiovascular	ARB/ thiazide diuretic	tablet
loteprednol etabonate	Ophthalmic	Corticosteroid	eye drops, eye gel
lurasidone	Central nervous system	Antipsychotic, atypical	tablet
magnesium oxide	Vitamin	Vitamin	capsule tablet
measles, mumps, rubella vaccine	Vaccines	Viral vaccine	injection
meclizine	Central nervous system	Antivertigo, antiemetic	tablet
medroxyprogesterone	Endocrine	Progestin	tablet, injection
megestrol	Gastrointestinal, appetite stimulant	Endocrine, progestin	tablet, oral liquid
meloxicam	Analgesic	Non-steroidal anti-inflammatory drug	capsule, tablet
meningococcal conjugate vaccine	Vaccines	Bacterial vaccine	injection
mesalamine	Gastrointestinal	5-Aminosalicylate	capsule, tablet, enema, rectal suppository
metformin	Antidiabetic	Biguanide	tablet
metformin/sitagliptin	Antidiabetic	Biguanide/DPP-4 inhibitor	tablet
methylcellulose	Gastrointestinal	Laxative, bulk-forming	oral powder, tablet
methylprednisolone	Endocrine	Glucocorticoid	tablet
metoclopramide	Gastrointestinal	Antiemetic, prokinetic	tablet, oral liquid, nasal sprayp
metoprolol succinate	Cardiovascular	Beta-blocker	capsule, tablet
metoprolol tartrate	Cardiovascular	Beta-blocker	tablet
metoprolol tartrate/hydrochlorothiazide	Cardiovascular	Beta-blocker/thiazide diuretic	tablet
metronidazole	Anti-infective	Amebicide, trichomonaside	capsule, tablet, topical
midodrine	Cardiovascular	Vasopressor	tablet
mirtazapine	Central nervous system	Tetracyclic antidepressant	tablet
modafinilcs	Central nervous system	Stimulant	tablet
mometasone	Respiratory or Dermatologic	Corticosteroid	inhaler, nasal spray, topical

Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024			
****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****			
CS indicates controlled substance. PA indicates prior authorization required.			
Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
mometasone/formoterol	Respiratory	Corticosteroid/long-acting Beta-2 agonist	inhaler
mometasone/olopatadine	Respiratory	Corticosteroid/antihistamine	nasal spray
montelukast	Respiratory	Leukotriene receptor antagonist	tablet, oral granules
moxifloxacin	Anti-infective	Quinolone antibiotic	tablet, eye drops
multivitamin	Vitamin	Vitamin	tablet
multivitamin prenatal	Vitamin	Vitamin	tablet
multivitamin with minerals	Vitamin	Vitamin	tablet
mupirocin	Dermatologic	Antibiotic	topical
naloxone	Substance abuse	Opiate antagonist	nasal spray, injection
naltrexone	Substance abuse	Opiate antagonist	capsule, tablet, injection
naltrexone ER/bupropion ER	Anti-obesity	Anoretic agents	tablet
naproxen	Analgesic	Nonsteroidal anti-inflammatory drug	tablet, oral liquid
naratriptan	Central nervous system	Antimigraine	tablet
nepafenac	Anti-inflammatory	Non-steroidal anti-inflammatory drug	eye drops
niacin	Cardiovascular, antihyperlipidemic	Vitamin, lipotropic	capsule, tablet
nicotine	Substance abuse	Nicotine replacement	gum, inhaler, lozenge, nasal spray, patch
nifedipine	Cardiovascular	Calcium channel blocker	capsule, tablet
nitrofurantoin	Anti-infective	Nitrofuan derivative	capsule, oral liquid
nitroglycerin	Cardiovascular	Vasodilating agents	capsule, nasal spray, tablet, topical
norethindrone	Endocrine	Progestin	tablet
nortriptyline	Central nervous system, antidepressant	Tricyclic antidepressant (TCA)	capsule, oral liquid
nystatin	Anti-infective	Antifungal	tablet, oral liquid, topical
olanzapine	Central nervous system	Antipsychotic, antimanic	tablet, injection
olmesartan	Cardiovascular	Angiotensin II receptor blocker	tablet
olmesartan/hydrochlorothiazide	Cardiovascular	ARB/ thiazide diuretic	tablet
olopatadine	Respiratory	Anti-histamine	eye drops, nasal spray
omega 3 (icosapent ethyl)	Cardiovascular, antihyperlipidemic	Lipotropic	capsule
omega-3-acid ethyl esters	Cardiovascular, antihyperlipidemic	Lipotropic	capsule
omeprazole	Gastrointestinal, acid reducing	Proton pump inhibitor	capsule, tablet, oral liquid
ondansetron	Central nervous system	Anti-nausea	tablet, oral film
orlistat	Anti-obesity	Gastrointestinal lipase inhibitor	capsule
oseltamivir	Anti-infective	Anti-influenza antiviral	capsule, oral liquid
oxybutynin	Genitourinary	Bladder antispasmodic	tablet, oral liquid, topical
oxycodone ^{CS}	Analgesic	Opiate	capsule, tablet, oral liquid
pancrelipase (amylase, lipase, protease)	Gastrointestinal	Pancreatic enzyme replacement	capsule, tablet
pantoprazole	Gastrointestinal, acid reducing	Proton pump inhibitor	tablet, oral granules, oral liquid
paromomycin	Anti-infective	Amebicide	capsule
paroxetine	Central nervous system, antidepressant	Selective serotonin reuptake inhibitor (SSRI)	capsule, tablet, oral liquid
penicillin	Anti-infective	Beta-lactam antibiotic	tablet, oral liquid, injection
permethrin	Dermatologic	Anti-infective, scabicide	topical
pioglitazone	Antidiabetic	Thiazolidinedione (glitazone)	tablet
pitavastatin	Cardiovascular, antihyperlipidemic	HMG-CoA reductase inhibitor	tablet

Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024			
****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****			
CS indicates controlled substance. PA indicates prior authorization required.			
Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
pneumococcal 15-valent conjugate vaccine	Vaccines	Bacterial vaccine	injection
pneumococcal 20-valent conjugate vaccine	Vaccines	Bacterial vaccine	injection
pneumococcal 23-polyvalent vaccine	Vaccines	Bacterial vaccine	injection
podofilox	Dermatologic	Antiviral	topical
polycarbophil	Gastrointestinal	Laxative, bulk-forming	tablet
polyethylene glycol and electrolytes	Gastrointestinal	Osmotic laxative	oral liquid
polyethylene glycol/propylene glycol	Ophthalmic	Lubricating agent	eye drops
polysaccharide-iron complex	Vitamin	Vitamin	capsule
potassium chloride	Cardiovascular	Electrolyte replacement	capsule, tablet, oral liquid
prasugrel	Cardiovascular	Platelet inhibitor	tablet
pravastatin	Cardiovascular, antihyperlipidemic	HMG-CoA reductase inhibitor	tablet
prazosin	Cardiovascular	Anti-hypertensive, Alpha-blocker	capsule
prednisolone	Endocrine	Corticosteroid	tablet, oral liquid, eye drops
prednisone	Endocrine	Corticosteroid	tablet, oral liquid
pregabalin ^{CS}	Central nervous system	Anticonvulsant, mood stabilizer	capsule, tablet, oral liquid
primaquine	Anti-infective	Antimalarial	tablet
promethazine	Gastrointestinal	Antihistamine, antiemetic	tablet, oral liquid, rectal suppository
propranolol	Cardiovascular	Beta-blocker	tablet, capsule, oral liquid
psyllium	Gastrointestinal	Laxative, bulk-forming	capsule, oral powder
pyrazinamide	Anti-infective	Antimycobacterial	tablet
pyridoxine (vitamin B6)	Vitamin	Vitamin	capsule, tablet, oral liquid
pyrimethamine	Anti-infective	Antimalarial	tablet
quetiapine	Central nervous system	Antipsychotic, antimanic	tablet
respiratory syncytial virus (RSV) vaccine	Vaccines	Viral vaccine	injection
respiratory syncytial virus (RSV) vaccine, adjuvanted	Vaccines	Viral vaccine	injection
ribavirin	Anti-infective	Hepatitis C antiviral	capsule, tablet
rifabutin	Anti-infective	Antimycobacterial	capsule
rifampin	Anti-infective	Antimycobacterial	capsule
rifapentine	Anti-infective	Antimycobacterial	tablet
rifaximin	Gastrointestinal	Anti-infective	tablet
risperidone	Central nervous system	Antipsychotic, atypical	tablet, oral liquid, injection
rivaroxaban	Blood formation and coagulation	Anticoagulant	tablet, oral liquid
rizatriptan	Central nervous system	Antimigraine	tablet
rosuvastatin	Cardiovascular, antihyperlipidemic	HMG-CoA reductase inhibitor	capsule, tablet
sacubitril/valsartan	Cardiovascular	Neprilysin inhibitor/ARB	tablet
SARS-CoV-2 (COVID 19) vaccine	Vaccines	Viral vaccine	injection
semaglutide	Antidiabetic	Glucagon-like peptide-1 receptor agonist (GLP-1 RA)	tablet, injection
sertraline	Central nervous system	Selective serotonin reuptake inhibitor (SSRI)	capsule, tablet, oral liquid
sildenafil	Genitourinary	Phosphodiesterase type 5 inhibitor	tablet, oral liquid
sitagliptin	Antidiabetic	Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor)	tablet
smallpox/monkeypox vaccine	Vaccines	Viral vaccine	injection
sofosbuvir/velpatasvir	Anti-infective	Hepatitis C antiviral	tablet, oral pellet packet

Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024			
****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****			
CS indicates controlled substance. PA indicates prior authorization required.			
Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
sofosbuvir/velpatasvir/voxilaprevir	Anti-infective	Hepatitis C antiviral	tablet
spironolactone	Cardiovascular	Potassium sparing diuretic	tablet, oral liquid
spironolactone/hydrochlorothiazide	Cardiovascular	Potassium sparing diuretic combinations	tablet
sucralfate	Gastrointestinal	Gastric acid buffer	tablet, oral liquid, mucosal paste
sulfadiazine	Anti-infective	Sulfonamide antibiotic	tablet
sulfamethoxazole/trimethoprim	Anti-infective	Sulfonamide antibiotic	tablet, oral liquid
sumatriptan	Central nervous system	Antimigraine	tablet, injection, nasal spray
tadalafil	Genitourinary	Phosphodiesterase type 5 inhibitor	tablet, oral liquid
tamsulosin	Genitourinary	Alpha-blocker	capsule
terazosin	Cardiovascular	Alpha-blocker	capsule
terconazole	Anti-infective	Azole antifungal	topical, vaginal suppository
testosteroneCS	Endocrine	Androgen	injection, gel, patch (note: testosterone undecanoate is nonformulary)
tetanus diphtheria (Td) vaccine	Vaccines	Bacterial vaccine	injection
tetanus diphtheria-acellular pertussis (Tdap) vaccine	Vaccines	Bacterial vaccine	injection
timolol	Antiglaucoma	Beta blocker	eye drops, tablet
tinidazole	Anti-infective	Amebicide, trichomonoaside	tablet
tiotropium	Respiratory	Anti-cholinergic, oral inhaled	inhaler
tiotropium/olodaterol	Respiratory	Long-acting muscarinic antagonist/long-acting Beta-2 agonist	inhaler
tizanidine	Central nervous system	Muscle relaxant	capsule, tablet
topiramate	Central nervous system	Anticonvulsant	capsule, tablet, oral liquid
tramadolCS	Analgesic	Opioid	capsule, tablet, oral liquid
travoprost	Antiglaucoma	Prostaglandin	eye drops
trazodone	Central nervous system, antidepressant	Serotonin reuptake inhibitor	tablet
tretinoin	Dermatologic	Anti-acne retinoid	capsule, topical
triamcinolone	Respiratory or Dermatologic	Corticosteroid	nasal spray, topical, oral paste
triamcinolone/nystatin	Dermatologic	Corticosteroid/antifungal	topical
triamterene/hydrochlorothiazide	Cardiovascular	Potassium sparing/thiazide diuretic	capsule
umeclidinium	Respiratory	Anticholinergic	inhaler
umeclidinium/vilanterol	Respiratory	Anticholinergic/long-acting Beta-2 agonist	inhaler
valacyclovir	Anti-infective	Antiherpetic antiviral	tablet
valganciclovir	Anti-infective	Antiherpetic antiviral (CMV)	tablet
valproic acid	Central nervous system	Anticonvulsant, mood stabilizer	capsule, oral liquid
valsartan	Cardiovascular	Angiotensin II receptor blocker (ARB)	tablet, oral liquid
valsartan/hydrochlorothiazide	Cardiovascular	ARB/ thiazide diuretic	tablet
vancomycin	Anti-infective	Glycopeptide antibiotic	capsule, oral liquid
varденаfil	Genitourinary	Phosphodiesterase type 5 inhibitor	tablet
varenicline	Smoking cessation	Partial nicotine agonist	tablet, nasal spray
venlafaxine	Central nervous system, antidepressant	Serotonin-norepinephrine reuptake inhibitor	capsule, tablet
verapamil	Cardiovascular	Calcium channel blocker	capsule, tablet
vitamin B complex	Vitamin	Vitamin	capsule, tablet
vitamin C	Vitamin	Vitamin	tablet

Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024			
****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****			
CS indicates controlled substance. PA indicates prior authorization required.			
Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
voriconazole	Anti-infective	Azole antifungal	tablet, oral liquid
warfarin	Blood formation and coagulation	Vitamin K antagonist	tablet
ziprasidone	Central nervous system	Antipsychotic, atypical	capsule, injection
zolpidemCS	Central nervous system	Sedative-hypnotic	capsule, tablet
zoster vaccine (recombinant)	Vaccines	Viral vaccine	injection



Medical Care Subcommittee

Friday, February 6, 2026

9:30 a.m. – 11:30 a.m.

Behavioral Science Research

2121 Ponce de Leon Blvd., Ste. 240

Miami, FL 33134

AGENDA

- | | | |
|-------|--|-----------------|
| I. | Call to Order | James Dougherty |
| II. | Introductions | All |
| III. | Meeting Housekeeping | James Dougherty |
| IV. | Floor Open to the Public | Cristhian Ysea |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 23, 2026 | All |
| VII. | Standing Business | |
| | • Response to the 2026 ADAP Program Changes- Updates | All |
| | • Formulary Reviews and Prioritization | All |
| | ○ Oral Health Formulary | |
| | ○ Prescription Drugs Formulary | |
| | ○ Allowable Conditions | |
| VIII. | Announcements | All |
| IX. | Next Meeting: February 27, 2026 at BSR | Cristhian Ysea |
| X. | Adjournment | James Dougherty |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/

Average Cost Per Client (Broken out by E/M Code Categories) FY 2024	
Evaluation and Management FY 2024	\$1,026.86
Anesthesiology FY 2024	\$274.78
Surgery FY 2024	\$143.12
Radiology FY 2024	\$290.62
Pathology and Laboratory FY 2024	\$762.36
Other Medicine (Except Anesthesiology) FY 2024	\$273.82
Average OAHS Cost Per Client (Total, FY 2024)	\$1,927.91
* These data were generated on 1/21/2026 and may differ slightly from Needs Assessment expenditure	

Sum Cost Per Client (Broken out by E/M Code Categories) FY 2024	
Evaluation and Management FY 2024	\$4,360,029.12
Anesthesiology FY 2024	\$25,280.00
Surgery FY 2024	\$395,871.31
Radiology FY 2024	\$159,841.36
Pathology and Laboratory FY 2024	\$3,115,000.84
Other Medicine (Except Anesthesiology) FY 2024	\$773,803.99
Aggregate OAHS Cost Per Client (Total, FY 2024)	\$8,829,826.62
* These data were generated on 1/21/2026 and may differ slightly from Needs Assessment expenditure	

**MIAMI-DADE COUNTY RYAN WHITE PROGRAM
ALLOWABLE MEDICAL CONDITIONS LIST**

These conditions are related to or exacerbated by HIV, comorbidities related to HIV, or complications of HIV treatment.

Conditions listed may be accessible under multiple specialties though not specifically referenced.

*This list is intended to address the federal Health Resources and Services Administration's requirement that services provided through outpatient medical care be related to an individual's HIV status. **This list is not exhaustive and is a sample guideline created to assist medical providers with specialty care referrals and to emphasize the importance of documenting the link between an individual's HIV status and the specialty care service to which a client is referred.***

Routine medical diagnostic testing (e.g., Pap smear, mammogram, bone density test, colonoscopy, colorectal cancer screening, optometry or ophthalmologic screening for eye health, etc.) is allowable as long as such testing follows established medical guidelines, such as U.S. Public Health Service (PHS), American Medical Association, Health Resources and Services Administration (HRSA), or other local guidelines, as a standard of care. Please see the most current, local Ryan White Program Service Delivery Manual for more information.

When provided in an outpatient setting, labs, diagnostics, and treatments related to HIV, as indicated above, including complications of HIV treatment related to the following conditions may be covered:

BONE AND JOINT DISEASES (E.G., ORTHOPEDICS/RHEUMATOLOGY):

osteoarthritis

**BONE AND JOINT DISEASES (E.G., ORTHOPEDICS/RHEUMATOLOGY) and
CHIROPRACTIC/PHYSICAL MEDICINE:**

avascular necrosis of hip, knee, etc. (Stage 1 or 2 only for CHIROPRACTIC/PHYSICAL MEDICINE)

fibromyalgia

myopathy/myalgia, HIV-related (chronic for CHIROPRACTIC/PHYSICAL MEDICINE)

osteopenia/osteoporosis

rheumatic diseases

CARDIOLOGY:

atherosclerosis

coronary artery disease

heart disease

hyperlipidemia

peripheral artery disease

phlebitis

CHIROPRACTIC/PHYSICAL MEDICINE:

HIV-related chronic arthralgia

peripheral neuropathy

IMPORTANT NOTE: According to CDC, chronic pain is defined as pain having duration of at least three months. Chronic pain is considered a co-morbidity of HIV. This may also contribute to the depression with pain comorbidity complex (DPC). Treatment of acute pain is not covered.

**MIAMI-DADE COUNTY RYAN WHITE PROGRAM
ALLOWABLE MEDICAL CONDITIONS LIST**

COLORECTAL:

abnormal anal Pap smears
fistulas
hernias

COLORECTAL and ONCOLOGY:

anal cancers

DENTAL (ORAL HEALTH CARE):

giant aphthous ulcers

DENTAL (ORAL HEALTH CARE); and EAR, NOSE and THROAT (ENT)/OTOLARYNGOLGY:

human papillomavirus associated oral lesions

**DENTAL (ORAL HEALTH CARE); EAR, NOSE and THROAT (ENT)/OTOLARYNGOLGY; and
ONCOLOGY:**

dental cancers
oral cancers

DERMATOLOGY:

dermatitis
eczema/seborrheic dermatitis
eosinophilic folliculitis
impetigo
Methicillin-resistant Staphylococcus aureus (MRSA)
molluscum contagiosum
photodermatitis
pruritus (as a symptom of undiagnosed xerosis, psoriasis, scabies, lymphoma, etc.)
psoriasis
skin conditions and symptoms, including skin appendages and oral mucosa
warts

DERMATOLOGY and GENITOURINARY (GU)/ GYNECOLOGY (GYN)/OBSTETRICS (OB):

tinea infections

DERMATOLOGY and INFECTIOUS DISEASES:

herpes simplex virus

DERMATOLOGY and ONCOLOGY:

Kaposi's sarcoma
skin cancers (squamous cell carcinoma, etc.)

DERMATOLOGY and PODIATRY:

onychomycosis

**MIAMI-DADE COUNTY RYAN WHITE PROGRAM
ALLOWABLE MEDICAL CONDITIONS LIST**

EAR, NOSE AND THROAT (ENT)/OTOLARYNGOLOGY:

chronic sinusitis
oral human papillomavirus

ENDOCRINOLOGY:

diabetes
hormone replacement therapy (for individuals of trans experience)
hypogonadism

GASTROINTESTINAL:

colitis (syphilitic colitis--very rare)
diarrhea
esophageal candidiasis
nausea/vomiting

GENITOURINARY (GU)/ GYNECOLOGY (GYN)/OBSTETRICS (OB):

abnormal Pap smear
cervical human papillomavirus
erectile dysfunction*
hematuria (related to neoplasms)
pregnancy
scrotal candidiasis
vaginitis

GENITOURINARY (GU)/ GYNECOLOGY (GYN)/OBSTETRICS (OB) and ONCOLOGY:

gynecological cancers
prostate cancer

**IMPORTANT NOTE: the local Ryan White Part A/MAI Program will only pay for evaluation and diagnostics of erectile dysfunction; but the treatment of erectile dysfunction is not covered by the local Ryan White Part A/MAI Program.*

HEMATOLOGY:

anemia
neutropenia
thrombocytopenia

HEMATOLOGY and ONCOLOGY:

polycythemia vera

INFECTIOUS DISEASE:

histoplasmosis
leishmaniasis
non-tuberculous mycobacterial infections
syphilis
varicella zoster infections
viral hepatitis (hepatitis B and C)

**MIAMI-DADE COUNTY RYAN WHITE PROGRAM
ALLOWABLE MEDICAL CONDITIONS LIST**

INFECTIOUS DISEASE and DERMATOLOGY:

Mpox

INFECTIOUS DISEASE and OPHTHAMOLOGY:

toxoplasmosis

INFECTIOUS DISEASE and PULMONOLOGY:

tuberculosis

MENTAL HEALTH SERVICES and PSYCHIATRY:

mental health disorder caused or exacerbated by HIV diagnosis or HIV treatment

mental health disorder/condition that significantly hinders a client's HIV treatment adherence

IMPORTANT NOTES

Under Mental Health Services, a mental health professional (PhD, EdD, PsyD, MA, MS, MSW, or M. Ed) will assess, diagnose, and treat mental illness under the mental health service category.

Under Psychiatry, a Psychiatrist will assess, diagnose, and treat mental illness in an outpatient/ambulatory health care setting.

NEPHROLOGY:

human immunodeficiency virus-associated nephropathy

renal failure (may be related to coronary artery disease induced by HIV or diabetes mellitus induced by HIV, etc.)

NEUROLOGY:

delirium

HIV-associated neurocognitive disorder (HAND) ^{1,2}

HIV- related encephalopathy

neuropathy

neurosyphilis

¹ National Institute of Mental Health info: <https://www.nimh.nih.gov/about/organization/dar/developmental-and-clinical-neuroscience-of-hiv-prevention-and-treatment-branch/clinical-neuroscience-of-hiv-infection-program>

[NOTE: old NIMH web link not accessible. Additional link added below by OMB-GC/Ryan White Program]

² UCSF Weill Institute for Neurosciences:

https://memory.ucsf.edu/sites/memory.ucsf.edu/files/wysiwyg/UCSF_HIV%20Dementia_Providers_11-6-17.pdf

NUTRITION:

lipodystrophy

wasting

weight gain

weight loss

**MIAMI-DADE COUNTY RYAN WHITE PROGRAM
ALLOWABLE MEDICAL CONDITIONS LIST**

ONCOLOGY:

Cancers-may include but not limited to: breast, eye (e.g., squamous cell carcinoma of the eye, etc.), lymphoma, polycythemia vera, prostate

IMPORTANT NOTE: the local Ryan White Part A/MAI Program is restricted to evaluation, diagnostics, and treatment in an outpatient setting.

OPHTHALMOLOGY/OPTOMETRY:

Clients must also meet at least one of these criteria to receive ophthalmology/optometry treatment services:

- Client has a low CD4 count (at or less than 200 cells/mm³) *currently*
- Client has a comorbidity (e.g., diabetes, hypertension, STI, etc.)
- Client has a prior diagnosis of cytomegalovirus retinitis (CMV)
- Client has Immune Reconstitution Syndrome

Referrals to an optometrist or ophthalmologist for treatment must indicate a condition related to or exacerbated by HIV, comorbidities related to HIV, or complications of HIV treatment. Referrals for treatment must be generated by an ophthalmological specialist. Any one of these conditions listed below would apply as examples.

Manifestations due to opportunistic infections:

- acute retinal necrosis
- bacterial retinitis
- candida endophthalmitis
- cryptococcus chorioretinitis
- cytomegalovirus retinitis
- pneumocystis choroiditis

Visual disturbances to rule out complication of HIV due to:

- cataracts
- dry eyes (sicca)
- glaucoma
- intra-retinal hemorrhages
- reactive arthritis
- trichomegaly or eyelash hypertrichosis (exaggerated growth of the eye lashes found in the later stages of the disease)
- uveitis

History of STI and complications of STI:

- herpes simplex virus
- herpes zoster-varicella visual changes
- syphilis

IMPORTANT NOTE: the local Ryan White Part A/MAI Program will only pay for evaluation, diagnostics and treatment for HIV-related eye problems/complications such as the examples listed above and will not pay for the filling of prescriptions for corrective lenses (e.g., [glasses or contact lenses for] astigmatism, myopia, hyperopia, [or presbyopia]).

[bracketed phrasing above was added by Miami-Dade County Ryan White Program Recipient for clarity.]

PODIATRY:

**MIAMI-DADE COUNTY RYAN WHITE PROGRAM
ALLOWABLE MEDICAL CONDITIONS LIST**

diabetic foot care
foot and ankle pain*
plantar fasciitis related to lipoatrophy and other known associated causes

**IMPORTANT NOTE: the local Ryan White Part A/MAI Program will only pay for evaluation, diagnosis, and treatment of foot and ankle pain for HIV related conditions or co-morbidities. Conditions such as hammer toes, bunions, and heel spurs may be covered if related to neuropathies. Sprains or fractures are not covered unless a direct connection to neuropathies is present.*

PULMONARY:

mycobacterium
pneumocystis pneumonia
recurrent pneumonia



Medical Care Subcommittee
Friday, February 6, 2026
9:30 a.m. – 11:30 a.m.
Behavioral Science Research
2121 Ponce de Leon Blvd., Ste. 240
Miami, FL 33134

AGENDA

- | | | |
|-------|--|-----------------|
| I. | Call to Order | James Dougherty |
| II. | Introductions | All |
| III. | Meeting Housekeeping | James Dougherty |
| IV. | Floor Open to the Public | Cristhian Ysea |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 23, 2026 | All |
| VII. | Standing Business | |
| | • Response to the 2026 ADAP Program Changes- Updates | All |
| | • Formulary Reviews and Prioritization | All |
| | ○ Oral Health Formulary | |
| | ○ Prescription Drugs Formulary | |
| | ○ Allowable Conditions | |
| VIII. | Announcements | All |
| IX. | Next Meeting: February 27, 2026 at BSR | Cristhian Ysea |
| X. | Adjournment | James Dougherty |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



Medical Care Subcommittee
Friday, February 6, 2026
9:30 a.m. – 11:30 a.m.
Behavioral Science Research
2121 Ponce de Leon Blvd., Ste. 240
Miami, FL 33134

AGENDA

- | | | |
|-------|--|-----------------------|
| I. | Call to Order | James Dougherty |
| II. | Introductions | All |
| III. | Meeting Housekeeping | James Dougherty |
| IV. | Floor Open to the Public | Cristhian Ysea |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 23, 2026 | All |
| VII. | Standing Business | |
| | • Response to the 2026 ADAP Program Changes- Updates | All |
| | • Formulary Reviews and Prioritization | All |
| | ○ Oral Health Formulary | |
| | ○ Prescription Drugs Formulary | |
| | ○ Allowable Conditions | |
| VIII. | Announcements | All |
| IX. | Next Meeting: February 27, 2026 at BSR | Cristhian Ysea |
| X. | Adjournment | James Dougherty |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/



Medical Care Subcommittee
Friday, February 6, 2026
9:30 a.m. – 11:30 a.m.
Behavioral Science Research
2121 Ponce de Leon Blvd., Ste. 240
Miami, FL 33134

AGENDA

- | | | |
|-------|--|------------------------|
| I. | Call to Order | James Dougherty |
| II. | Introductions | All |
| III. | Meeting Housekeeping | James Dougherty |
| IV. | Floor Open to the Public | Cristhian Ysea |
| V. | Review/Approve Agenda | All |
| VI. | Review/Approve Minutes of January 23, 2026 | All |
| VII. | Standing Business | |
| | • Response to the 2026 ADAP Program Changes- Updates | All |
| | • Formulary Reviews and Prioritization | All |
| | ○ Oral Health Formulary | |
| | ○ Prescription Drugs Formulary | |
| | ○ Allowable Conditions | |
| VIII. | Announcements | All |
| IX. | Next Meeting: February 27, 2026 at BSR | Cristhian Ysea |
| X. | Adjournment | James Dougherty |

Please turn off or mute cellular devices – Thank you

For more information, regarding the Miami-Dade HIV/AIDS Partnership's Medical Care Subcommittee please contact Marlen Meizoso at 305-445-1076 or marlen@behavioralscience.com

Follow Us: www.PartnershipMiami.org | facebook.com/HIVPartnership | instagram.com/hiv_partnership/